Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review

Parkinsonism and Related Disorders

Volumn 21, Issue 7, 2015, Pages 683-691

  Lenka, Abhishek ^a   Jhunjhunwala, Ketan Ramakant ^a   Saini, Jitender ^a   Pal, Pramod Kumar ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

FMRI; Parkinson's disease; PET; SPECT; VBM; Visual hallucinations

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ATTENTION; AUDITORY HALLUCINATION; BECK DEPRESSION INVENTORY; BRAIN SIZE; CASE CONTROL STUDY; CINGULATE GYRUS; COGNITIVE DEFECT; DEPTH PERCEPTION; DISEASE SEVERITY; DORSAL ATTENTION NETWORK; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; LIMBIC SYSTEM; LONGITUDINAL STUDY; MEMORY; MEYNERT BASAL NUCLEUS; NURSING HOME; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; SUBSTANTIA INNOMINATA; VISUAL ASSOCIATION CORTEX; VISUAL CORTEX; VISUAL HALLUCINATION; VOXEL BASED MORPHOMETRY; HALLUCINATIONS; PROCEDURES; PSYCHOLOGY;

FUNCTIONAL NEUROIMAGING; HALLUCINATIONS; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84930762296     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.04.005     Document Type: Review

References (56)

1. De Lau L.M.L., Breteler M.M.B. Epidemiology of Parkinson's disease. Lancet Neurol 2006 Jun, 5(6):525-535.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. JNeurol Neurosurg Psychiatry 2008 Apr, 79(4):368-376.
3. Chaudhuri K.R., Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21:916-923.
4. Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., MacPhee G., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22:1623-1629.
5. Aarsland D., Larsen J.P., Tandberg E., Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. JAm Geriatr Soc 2000, 48:938-942.
6. Marsh L., Williams J.R., Rocco M., Grill S., Munro C., Dawson T.M. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004, 63:293-300.
7. Forsaa E.B., Larsen J.P., Wentzel-Larsen T., Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010, 75:1270-1276.
8. Fénelon G., Alves G. Epidemiology of psychosis in Parkinson's disease. JNeurol Sci 2010 Feb 15, 289(1-2):12-17. Elsevier B.V.
9. Goetz C.G., Fan W., Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov Disord 2008 Aug 15, 23(11):1541-1545.
10. Fénelon G., Mahieux F., Huon R., Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain J Neurol 2000, 733-745.
11. Harding A.J., Stimson E., Henderson J.M., Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002 Nov, 125(Pt 11):2431-2445.
12. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
13. Ramírez-Ruiz B., Martí M.-J., Tolosa E., Giménez M., Bargalló N., Valldeoriola F., et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007, 14:750-756.
14. Lee H.W., Hong S.B., Seo D.W., Tae W.S., Hong S.C. Mapping of functional organization in human visual cortex: electrical cortical stimulation. Neurology 2000, 54:849-854.
15. Clark V.P., Maisog J.M., Haxby J.V. fMRI study of face perception and memory using random stimulus sequences. JNeurophysiol 1998, 3257-3265.
16. Lambert S., Sampaio E., Mauss Y., Scheiber C. Blindness and brain plasticity: contribution of mental imagery? an fMRI study. Cogn Brain Res 2004, 20:1-11.
17. Kastner S., Pinsk M.A., De Weerd P., Desimone R., Ungerleider L.G. Increased activity in human visual cortex during directed attention in the absence of visual stimulation. Neuron 1999, 22:751-761.
18. Pagonabarraga J., Soriano-Mas C., Llebaria G., López-Solà M., Pujol J., Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Park Relat Disord 2014 Mar, 20(3):290-296. Elsevier Ltd.
19. Ibarretxe-Bilbao N., Ramírez-Ruiz B., Tolosa E., Martí M.J., Valldeoriola F., Bargalló N., et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. JNeurol 2008 Sep, 255(9):1324-1331.
20. Iacono D., O'Brien R., Resnick S.M., Zonderman A.B., Pletnikova O., Rudow G., et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. JNeuropathol Exp Neurol 2008, 67:578-589.
21. Ibarretxe-Bilbao N., Ramirez-Ruiz B., Junque C., Marti M.J., Valldeoriola F., Bargallo N., et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. JNeurol Neurosurg Psychiatry 2010 Jun, 81(6):650-657.
22. Manganelli F., Vitale C., Santangelo G., Pisciotta C., Iodice R., Cozzolino A., et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinsons disease. Brain 2009, 132:2350-2355.
23. Diederich N.J., Fénelon G., Stebbins G., Goetz C.G. Hallucinations in Parkinson disease. Nat Rev Neurol 2009, 5:331-342.
24. Perry E.K., Irving D., Kerwin J.M., McKeith I.G., Thompson P., Collerton D., et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993, 7:69-79.
25. Janzen J., van 't Ent D., Lemstra A.W., Berendse H.W., Barkhof F., Foncke E.M. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. JNeurol 2012 Jan, 259(1):147-154.
26. Zweig R.M., Jankel W.R., Hedreen J.C., Mayeux R., Price D.L. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989, 26:41-46.
27. Jenkinson N., Nandi D., Muthusamy K., Ray N.J., Gregory R., Stein J.F., et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord 2009, 319-328.
28. Lippa C.F., Smith T.W., Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. JNeural Transm 1999, 106:525-535.
29. Shin S., Lee J.E., Hong J.Y., Sunwoo M., Sohn Y.H., Lee P.H. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease 2012, 1155-1162.
30. Choi S.H., Jung T.M., Lee J.E., Lee S., Sohn Y.H., Lee P.H. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging 2012 Jul, 33(7):1265-1272. Elsevier Inc.
31. Gama R.L., Bruin V.M.S., Távora D.G.F., Duran F.L.S., Bittencourt L., Tufik S. Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn 2014 Jun, 87:97-103. Elsevier Inc.
32. Sommer I.E., Clos M., Meijering A.L., Diederen K.M.J., Eickhoff S.B. Resting state functional connectivity in patients with chronic hallucinations. PLoS One 2012, 7.
33. Sadaghiani S., D'Esposito M. Functional characterization of the cingulo-opercular network in the maintenance of tonic alertness. Cereb Cortex 2014, [epub ahead of print].
34. Watanabe H., Senda J., Kato S., Ito M., Atsuta N., Hara K., et al. Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination. Mov Disord 2013 Oct, 28(12):1732-1736.
35. Goldman J.G., Stebbins G.T., Dinh V., Bernard B., Merkitch D., Detoledo-Morrell L., et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain 2014, 137:849-859.
36. Meppelink A.M., de Jong B.M., Teune L.K., van Laar T. Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. Mov Disord 2011 Jan, 26(1):142-147.
37. Stebbins G.T., Goetz C.G., Carrillo M.C., Bangen K.J., Turner D.A., Glover G.H., et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004 Oct 26, 63(8):1409-1416.
38. Holroyd S., Wooten G.F. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. JNeuropsychiatry Clin Neurosci 2006, 402-404.
39. Ramírez-Ruiz B., Martí M.-J., Tolosa E., Falcón C., Bargalló N., Valldeoriola F., et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord 2008, 23:2335-2343.
40. Lumer E.D., Rees G. Covariation of activity in visual and prefrontal cortex associated with subjective visual perception. Proc Natl Acad Sci U. S. A 1999, 96:1669-1673.
41. Yao N., Shek-Kwan Chang R., Cheung C., Pang S., Lau K.K., Suckling J., et al. The default mode network is disrupted in parkinson's disease with visual hallucinations. Hum Brain Mapp 2014 Nov, 35(11):5658-5666.
42. Nagano-Saito A., Washimi Y., Arahata Y., Iwai K., Kawatsu S., Ito K., et al. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord 2004, 19:801-806.
43. Tomita H., Ohbayashi M., Nakahara K., Hasegawa I., Miyashita Y. Top-down signal from prefrontal cortex in executive control of memory retrieval. Nature 1999, 401:699-703.
44. Boecker H., Ceballos-Baumann A.O., Volk D., Conrad B., Forstl H., Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007, 64:984-988.
45. Park H.K., Kim J.S., Im K.C., Kim M.J., Lee J.-H., Lee M.C., et al. Visual hallucinations and cognitive impairment in Parkinson's disease. Can J Neurol Sci 2013 Sep, 40(5):657-662.
46. Okada K., Suyama N., Kobayashi S., Oguro H., Yamaguchi S. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. JNeurol 1999 May 26, 246(5):365-368.
47. Gloor P., Olivier A., Quesney L.F., Andermann F., Horowitz S. The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann Neurol 1982 Aug, 12(2):129-144.
48. Moskovitz C., Moses H., Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978, 135:669-675.
49. Graham J.M., Grunewald R.A., Sagar H.J. Hallucinosis in idiopathic Parkinson's disease. JNeurol Neurosurg Psychiatry 1997, 434-440.
50. Zoldan J., Friedberg G., Goldberg-Stern H., Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993 Feb 27, 341(8844):562-563.
51. Oishi N., Udaka F., Kameyama M., Sawamoto N., Hashikawa K., Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005, 65:1708-1715.
52. Shapiro K., Hillstrom A.P., Husain M. Control of visuotemporal attention by inferior parietal and superior temporal cortex. Curr Biol 2002, 12:1320-1325.
53. Matsui H., Nishinaka K., Oda M., Hara N., Komatsu K., Kubori T., et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord 2006 Dec, 21(12):2140-2144.
54. 123I-FP-CIT SPECT study. Park Relat Disord 2014 Jul, 20(7):761-765. Elsevier Ltd.
55. Ravina B., Marek K., Eberly S., Oakes D., Kurlan R., Ascherio A., et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012, 27:1392-1397.
56. Shine J.M., Halliday G.M., Naismith S.L., Lewis S.J.G. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks?. Mov Disord 2011, 26:2154-2159.